Literature DB >> 25621091

Idiopathic hypereosinophilic syndrome: a rare cause of erythroderma.

Vikram K Mahajan1, Ravinder Singh1, Karaninder S Mehta1, Pushpinder S Chauhan1, Saurabh Sharma2, Mrinal Gupta1, Ritu Rawat1.   

Abstract

BACKGROUND: Idiopathic hypereosinophilic syndrome (HES) is a rare and potentially lethal disorder characterized by persistently elevated eosinophil counts without any underlying causes. Two variants, the myeloproliferative and lymphocytic hypereosinophilic syndrome, have been identified. The symptoms are variable and related to the organs involved (cardiovascular system, skin, central and peripheral nervous system, gastrointestinal tract, eyes). Skin lesions can be the dominating and/or presenting symptom in about 50% of patients. MAIN OBSERVATIONS: We describe a 54-year-old man with a 12-year history of skin lesions, clinically consistent with psoriasis and psoriatic erythroderma. The patient was treated with methotrexate with no response. He experienced intense pruritus, dry/coarse skin and palmoplantar hyperkeratosis. Histopathology showed spongiotic dermatitis with no epidermotropism. Inflammatory infiltrates in upper dermis consisted predominantly of lymphocytes and eosinophils. Peripheral and tissue eosinophilia, immunophenotyping, and results of FIP1L1-PDGFRA gene analysis were suggestive of lymphocytic HES. The patient was treated with hydroxycarbamide (1 g/day), prednisolone (40 mg/day) and antihistamines with improvement.
CONCLUSIONS: HES requires early treatment to prevent severe damage of targeted organs. The pleomorphic dermatological manifestations may delay the diagnosis. This case shows the importance of wide differential diagnosis of erythroderma. In this article we discuss the diagnostic criteria, the recommended work-up and management of idiopathic hypereosinophilic syndrome variants.

Entities:  

Keywords:  Sézary syndrome; eosinophilia; erythroderma; hydroxycarbamide; hypereosinophilic syndrome; itch; palmoplantar hyperkeratosis; pruritus

Year:  2014        PMID: 25621091      PMCID: PMC4299705          DOI: 10.3315/jdcr.2014.1185

Source DB:  PubMed          Journal:  J Dermatol Case Rep        ISSN: 1898-7249


  17 in total

Review 1.  Practical approach to the patient with hypereosinophilia.

Authors:  Florence Roufosse; Peter F Weller
Journal:  J Allergy Clin Immunol       Date:  2010-06-09       Impact factor: 10.793

Review 2.  Cytogenetic and molecular genetic aspects of eosinophilic leukaemias.

Authors:  Barbara J Bain
Journal:  Br J Haematol       Date:  2003-07       Impact factor: 6.998

Review 3.  Advances in diagnosis and treatment of eosinophilia.

Authors:  Javed Sheikh; Peter F Weller
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

Review 4.  World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.

Authors:  Jason Gotlib
Journal:  Am J Hematol       Date:  2011-08       Impact factor: 10.047

Review 5.  Clinical management of the hypereosinophilic syndromes.

Authors:  Elie Cogan; Florence Roufosse
Journal:  Expert Rev Hematol       Date:  2012-06       Impact factor: 2.929

6.  Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.

Authors:  Jorge Cortes; Patricia Ault; Charles Koller; Deborah Thomas; Alessandra Ferrajoli; William Wierda; Mary B Rios; Laurie Letvak; Elizabeth S Kaled; Hagop Kantarjian
Journal:  Blood       Date:  2003-02-20       Impact factor: 22.113

Review 7.  Refining the definition of hypereosinophilic syndrome.

Authors:  Hans-Uwe Simon; Marc E Rothenberg; Bruce S Bochner; Peter F Weller; Andrew J Wardlaw; Michael E Wechsler; Lanny J Rosenwasser; Florence Roufosse; Gerald J Gleich; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2010-07       Impact factor: 10.793

Review 8.  Recent advances in pathogenesis and management of hypereosinophilic syndromes.

Authors:  F Roufosse; E Cogan; M Goldman
Journal:  Allergy       Date:  2004-07       Impact factor: 13.146

9.  A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5.

Authors:  D Brugnoni; P Airó; G Rossi; A Bettinardi; H U Simon; L Garza; C Tosoni; R Cattaneo; K Blaser; A Tucci
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

Review 10.  Lymphocytic variant hypereosinophilic syndromes.

Authors:  Florence Roufosse; Elie Cogan; Michel Goldman
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

View more
  1 in total

1.  Case for diagnosis. Erythroderma as manifestation of hypereosinophilic syndrome.

Authors:  Maira Renata Merlotto; Lucas Oliveira Cantadori; Delmo Sakabe; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.